BPH & Male LUTS INJ 2010;14:

Size: px
Start display at page:

Download "BPH & Male LUTS INJ 2010;14:"

Transcription

1 BPH & Male LUTS INJ 2010;14: Changes in Serum Prostate-Specific Antigen after Treatment with Antibiotics in Patients with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia with Prostatitis Yoon-Soo Kyung, Hyeoung-Cheol Lee, Hyung-Jee Kim Department of Urology, Dankook University College of Medicine, Cheonan, Korea Purpose: Many urologists have performed prostate biopsy in men with a high level of prostate-specific antigen (PSA) alone. However, high levels of PSA may be induced by infection. We studied the effects of antibiotics on serum total PSA and PSA density (PSAD) in men with total PSA between 4 and 10 ng/ml and normal digital rectal examination (DRE) and transrectal sonographic findings. Materials and Methods: From January 2005 to October 2009, a total of 107 patients with complaints of lower urinary tract symptoms (LUTS) or benign prostatic hyperplasia (BPH) were evaluated. To be included in this study, patients had to be at least 50 years old, have a palpably normal DRE, have infection in the prostate, have a total serum PSA of 4 to 10 ng/ml, and have transrectal ultrasound findings that did not show a hypoechoic lesion in the prostate. Only patients in whom the PSA level was rechecked after short-term antibiotics administration (8 weeks) were included. Serum PSA and PSAD were measured before transrectal ultrasound or EPS and after 8 weeks of treatment with antibiotics (quinolone). Age, prostate volume, serum PSA, PSAD, and PSA rate of change were compared. Results: The mean age of the patients was 66.3 years. The mean prostate size was 48.8±24.9 g. Forty patients had a high level of PSAD. Total PSA and PSAD significantly decreased after treatment (p <0.05). In 45 of the 107 men, total PSA after antibiotics treatment was normalized (less than 4 ng/ml). PSAD after treatment was normalized (less than 0.15 ng/ml/cm 3 ) in 23 of the 40 patients with a high level of PSAD. Conclusion: Antibiotics treatment for at least 8 weeks in BPH patients with an increased PSA level (4-10 ng/ml), infection, and normal DRE and transrectal sonographic findings may decrease serum PSA significantly. However, because the PSA level was not decreased to the normal range (less than 4 ng/ml) in all patients, it seems that antibiotics therapy before prostatic biopsy is not necessary. Key Words: Prostate-specific antigen; Antibiotics Introduction The elderly population is gradually increasing in Korea, and more of the population eats a Western diet. The incidence of prostate cancer also increases with age; more than 75% of diagnosed cancers are in men older than 65 years of age [1,2]. When prostate cancer is diagnosed too late, the course of the prostate cancer will have a poor progression [3]. However, patients diagnosed with Corresponding Author: Hyung-Jee Kim Department of Urology, Dankook University College of Medicine, Anseo-dong, Cheonan , Korea Tel: / Fax: / killtumor@yahoo.co.kr Submitted: June 26, 2010 / Accepted (with revisions): August 23, 2010 INJ is available at DOI: /inj

2 Changes in PSA after Antibiotics in LUTS/BPH 101 early prostate cancer have a significantly better survival rate. Thus, effort was made for the early detection of prostate cancer [4]. Currently, tests for the early diagnosis of prostate cancer include the digital rectal examination (DRE), transrectal prostate ultrasound, and serum prostate-specific antigen (PSA). Catalona et al. concluded that the use of PSA in conjunction with DRE enhances early prostate cancer detection, and prostatic biopsy should be considered if either the PSA level is greater than 4 micrograms/l or the DRE is suspicious for cancer, even in the absence of abnormal transrectal ultrasonography findings [5]. Also, the PSA test has a higher reproducibility and a relatively lower cost and is simple for the early diagnosis of prostate cancer. However, isolated serum PSA levels in individuals have not demonstrated sufficient sensitivity and specificity to be useful in the routine evaluation of prostate disease [8-10]. Many studies have reported that an elevated PSA level is related to prostatitis [6-9]. However, in a recent study, it was reported that although antibiotics therapy will decrease serum total PSA, it will not decrease the risk of prostate cancer even if the PSA decreases to less than 4 ng/ml [10]. Therefore, the aim of this study was to evaluate the effects of antibiotics on serum total PSA and PSA density (PSAD) in men with PSA between 4 and 10 ng/ml and normal DRE and transrectal ultrasound findings. Materials and Methods Form January 2005 to October 2009, a total of 107 patients with complaints of lower urinary tract symptoms (LUTS) or benign prostatic hyperplasia (BPH) were evaluated in this study. To be included in the present analysis, patients had to be at least 50 years old, have a palpably normal DRE, have a total serum PSA of 4 to 10 ng/ml, and have transrectal ultrasound findings that did not show a hypoechoic lesion in the prostate. Only patients in whom the PSA level was rechecked after short-term antibiotics use (8 weeks) were included. Patients with symptoms of acute prostatitis were excluded. Also, patients with a history of acute urinary retention, pyuria, an indwelling catheter, or previous prostate surgery or who had taken 5-alpha reductase enzyme inhibitors were excluded from the study. Chronic nonbacterial prostatitis is diagnosed by normal findings in urinalysis and more than 20 white blood cells in smear expressed prostatic secretion (EPS) under microscope with a high magnification view ( 400). Serum PSA and PSAD were measured before transrectal ultrasound or EPS and after 8 weeks of treatment with antibiotics (quinolone). Age, prostate volume, serum PSA, PSAD, and PSA rate of change were compared. PSA relative change (%) was defined as first serum PSA/ (first serum PSA - PSA after antibiotics treatment) 100. These data were analyzed statistically by using SPSS 8.0. The results were expressed as means±sd. Student s t-test was used to compare the mean values of continuous variables. A p-value less than 0.05 was considered significant. Results A total of 107 patients were enrolled in this study. The mean age of the patients was 66.3 years (range, 50 to 83 years). The mean prostate size was 48.8±24.9 g (range, g). Of these patients, the mean total PSA was 6.3±1.9 ng/ml and 4.8±2.4 ng/ml before and after treatment, respectively. There was a significant difference in the total PSA (p<0.05). In the same period, PSAD changed from 0.15±0.08 ng/ml/cm 3 to 0.11±0.07 ng/ml/cm 3 before and after treatment, respectively, which also showed a significant difference (p<0.05). The mean PSA rate of change was -23.8% at the same time. After 8 weeks of quinolone administration, the elevated total PSA level of 45 patients (42.1%) was normalized. Forty patients had a PSAD above 0.15 ng/ml/cm 3. Of these, PSAD was normalized in 23 cases (57.5%) after 8 weeks of quinolone administration. After 8 weeks of antibiotics treatment, in patients with a total PSA level of more than 4 ng/ml, 25 patients wanted more medication, but after four more weeks of treatment, the total PSA was decreased to 4 ng/ml in 8 cases (32%) (Table 1). INJ Vol. 14, No. 2, 2010

3 102 YS Kyung, et al. Table 1. Changes in pre- and post-treatment parameters No. of Patients 107 Mean Age 66.3 years old Prostatic size 48.8±24.9 g Pre post normalized patients (%) tpsa (ng/ml) 6.3± *±2.4 45/107 PSAD (ng/ml/cm 3 ) 0.15± *± /40 The results were expressed as means±sd. * expressed significant difference (p<0.05). Discussion After Hara et al identified PSA as a gamma-semino protein from the seminal plasma [11], Wang et al. reported the possibility that PSA might be a tumor marker for prostate cancer [12] and Papsidero et al. applied PSA to the clinical diagnosis of early prostate cancer and the follow-up of prostate cancer patients [13]. However, because PSA is a serine protease secreted by prostate epithelial cells [14] as well as primary gastric, mammary gland, and breast cancer tissue [15], PSA is nonspecific to the prostate. Moreover, the PSA level is increased by prostate cancer as well as by BPH, prostatitis, and other circumstances such as prostate biopsy, DRE, and acute urinary retention [16,17]. This leads to potentially unnecessary biopsy procedures [18]. Another study revealed that the lack of specificity of PSA measurement as the only biopsy indicator is most easily pointed out by the observation that in only 20% to 30% of biopsied men with a PSA value greater than 4.0 ng/ml is prostate cancer detected thus, approximately 70% to 80% of these men have a false-positive test result [19]. After Dalton et al. reported [20] that the PSA level of patients with acute prostatitis was increased and normalized after antibiotics use, Neal et al. reported [21] that chronic prostatitis results in changes in PSA. In another study, prostate volume and inflammation were reported to be the most important factors contributing to serum PSA elevation in men without clinically detectable prostate cancer [6]. Prostatitis must be considered when using PSA as a tumor marker because the PSA level decreases to normal after effective antibiotics therapy in most patients with bacterial prostatitis [7,8]. However, little is known about the relationship between the serum PSA level and the inflammatory state in BPH, and there are few Korean reports on the analysis of PSA changes in asymptomatic or mild symptomatic patients. According to a Korean study of middle-aged and older men with prostatitis, among 39 men, serum PSA and PSAD values returned to the normal range after antibiotics treatment in 22 (56.4%). It was suggested that prostatitis was one of the most important factors in serum PSA and PSAD elevation in men without clinically detectable prostate cancer and that a decrease in PSA and PSAD after antibiotics treatment can help to avoid unnecessary prostate biopsies [22]. However, in a recent study, there was no significant difference in the PSA levels of men with and without prostate inflammation [23]. Baltacı et al. reported that although antibiotics therapy will decrease serum total PSA, it will not decrease the risk of prostate cancer even if the PSA decreases to less than 4 ng/ml therefore, prescribing antibiotics for asymptomatic men with a newly increased PSA may not be an appropriate method of management [10]. The duration of antibiotics treatment was between 20 and 28 days in other studies [10,22]. Because the duration of antibiotics treatment has not been confirmed, we treated for 8 weeks based on the fact that in chronic bacterial prosta- INJ August 2010

4 Changes in PSA after Antibiotics in LUTS/BPH 103 titis and inflammatory CPPS, a total treatment period of 4 to 6 weeks has been recommended [24]. In our study, even though total PSA was decreased significantly after 8 weeks of treatment with antibiotics, and total PSA and PSAD were normalized in approximately 50% of patients, the total PSA and PSAD of all patient were not decreased to the normal range (less than 4 ng/ml). Thus, it seems that antibiotics therapy is not necessary. Conclusions Antibiotics treatment for at least 8 weeks in BPH patients with an increased PSA level (4-10 ng/ml), prostatitis, and normal DRE and transrectal sonographic findings may decrease serum PSA significantly. However, because total PSA and PSAD were not decreased to the normal range (less than 4 ng/ml) in all patients, it seems that antibiotics therapy is not necessary. References 1) Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, CA Cancer J Clin 1998;48:6-29 2) Hahnfeld LE, Moon TD. Prostate cancer. Med Clin North Am 1999;83: ) Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993;118: ) Schmidt J, Mettlin C, Natarajan N, Peace BB, Beart RW, Winchester DP, et al. Trends in pattern of care for prostatic cancer, : results of surveys by the American College of Surgeons. J Urol 1986;136: ) Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151: ) Nadler RB, Hymphrey PA, Smith DS, Catalona WJ, Ratiff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995;154: ) Pansadoro V, Emiliozzi P, Defidio L, Scarpone P, Sabatini G, Brisciani A, et al. Prostate-specific antigen and prostatitis in men under fifty. Eur Urol 1996;30:24-7 8) Cho IR, Kim GJ, Park SS, Choi HS. PSA and prostatitis in men under 45 years old. Korean J Urol 1998;39: ) Ozden C, Ozdal OL, Guzel O, Han O, Seckin S, Memis A. The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. Int Urol Nephrol 2007;39: ) Baltacı S, Süer E, Haliloğlu AH, Gokce MI, Elhan AH, Bedük Y. Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. J Urol 2009;181: ) Hara M, Koyanagi Y, Inoue T, Fukuyama T. Some physico-chemical characteristics of "-seminoprotein", an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII. Nippon Hoigaku Zasshi 1971;25: ) Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of human prostate specific antigen. Invest Urol 1979;17: ) Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980;40: ) Lilja H. Structure, function, and regulation of the enzyme activity of prostate-specific antigen. World J Urol 1993;11: ) Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 1997;24: ) Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145: ) Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317: ) Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 1997;24: ) Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 2004;63: ) Dalton DL. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology 1989;33: ) Neal DE Jr, Clejan S, Serma D, Moon TD. Prostate-specific antigen and prostatitis. I, Effect of prostatitis on serum PSA in the human and non- INJ Vol. 14, No. 2, 2010

5 104 YS Kyung, et al. human primate. Prostate 1992;20: ) Cho IR, Chang YS, Roh JS, Jeon JS, Park SS. Change of PSA and PSAD after antibiotic treatment in patients with prostatitis. Korean J Androl 2002; 20: ) Nickel JC, Roehborn CG, O Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008;54: ) Grabe M, Bishop MC, Bjerklund-Johansen TE, Botto H, Çek M, Lobel B, et al. Guidelines on urological infections. In: European Association of Urology Guideline 2009 edition. European Association of Urology 2009; INJ August 2010

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy? Original Article Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy? Sherif Azab 1, Ayman Osama 2, Mona Rafaat 3 1 Urology Department, Faculty

More information

Is Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen?

Is Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen? www.kjurology.org http://dx.doi.org/1.4111/kju.1.3..8 Urological Oncology Is Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen? Jee

More information

Kathmandu University Medical Journal (2010), Vol. 8, No. 2, Issue 30,

Kathmandu University Medical Journal (2010), Vol. 8, No. 2, Issue 30, Kathmandu University Medical Journal (2010), Vol. 8, No. 2, Issue 30, 158-163 Original Research Article Correlation of serum free prostate-specific antigen level with histological findings in patients

More information

Prostate Cancer Screening Guidelines in 2017

Prostate Cancer Screening Guidelines in 2017 Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate

More information

The Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend

The Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend www.kjurology.org http://dx.doi.org/1.4111/kju.212.53.1.686 Urological Oncology The Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend Hyung-Sang

More information

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon

More information

Role of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy

Role of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53..46 Urological Oncology Role of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy

More information

Enzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum

Enzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum Enzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum FOR RESEARCH USE ONLY Store at 2 to 8 C. PROPRIETARY AND COMMON NAMES f-psa Enzyme Immunoassay

More information

Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients

Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients (2003) 6, 256 260 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients 1, *

More information

Asian J Androl 2005; 7 (2): DOI: /j x

Asian J Androl 2005; 7 (2): DOI: /j x Asian J Androl 5; 7 (2): 159 163 DOI: 1.1111/j.1745-7262.5.29.x. Original Article. Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate

More information

Disease State Prostatitis Indicator Classification Disease Management Strength of Recommendation

Disease State Prostatitis Indicator Classification Disease Management Strength of Recommendation Client HMSA: PQSR 2009 Measure Title DIAGNOSTIC WORKUP OF CHRONIC PROSTATITIS Disease State Prostatitis Indicator Classification Disease Management Strength of Recommendation B Organizations Providing

More information

Histopathological Study of Transrectal Ultrasound Guided Biopsies of Prostate

Histopathological Study of Transrectal Ultrasound Guided Biopsies of Prostate ORIGINAL ARTICLE Histopathological Study of Transrectal Ultrasound Guided Biopsies of Prostate in Patients With Raised Serum Prostate Specific Antigen Prabha Rathour 1, Hetal Jani 2, Urvi Parikh 3, Hansa

More information

PSA screening. To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine

PSA screening. To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine PSA screening To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine Conflict of Interest Declaration: Nothing to Disclose

More information

Safety and Efficacy of Combined Transrectal Ultrasound-Guided Prostate Needle Biopsy and Transurethral Resection of the Prostate

Safety and Efficacy of Combined Transrectal Ultrasound-Guided Prostate Needle Biopsy and Transurethral Resection of the Prostate www.kjurology.org DOI:10.4111/kju.2010.51.2.101 Urological Oncology Safety and Efficacy of Combined Transrectal Ultrasound-Guided Prostate Needle Biopsy and Transurethral Resection of the Prostate Jeong

More information

KEY WORDS : Total Prostate Specific Antigen, Prostatic Acid Phosphatase, Benign Prostatic Hyperplasia, Prostate Cancer, and Sudanese.

KEY WORDS : Total Prostate Specific Antigen, Prostatic Acid Phosphatase, Benign Prostatic Hyperplasia, Prostate Cancer, and Sudanese. International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 3 Issue 1 January 2014 PP.36-40 Serum Total Prostatic Specific Antigen and Prostatic Acid

More information

ISSN X (Print) Pradesh. *Corresponding author Dr. Ashish

ISSN X (Print)   Pradesh. *Corresponding author Dr. Ashish Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2015; 3(8B):2886-2890 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)

More information

The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial

The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial european urology 54 (2008) 1379 1384 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia The Relationship between Prostate Inflammation and Lower Urinary

More information

Evaluation of Prostate Specific Antigen as a Tumor Marker in Cancer Prostate

Evaluation of Prostate Specific Antigen as a Tumor Marker in Cancer Prostate Evaluation of Prostate Specific Antigen as a Tumor Marker in Cancer Prostate Pages with reference to book, From 360 To 363 Farkhanda Ghafoor,Shahzad Khan,Bilquis Suleman,Aman Ullah Khan ( Departments of

More information

THE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE BIOPSIES IN IMPROVING THE DIAGNOSTIC ABILITY IN PROSTATE CANCER

THE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE BIOPSIES IN IMPROVING THE DIAGNOSTIC ABILITY IN PROSTATE CANCER Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 27 (3): 222-226, May - June, 2001 THE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE

More information

An Anteriorly Positioned Midline Prostatic Cyst Resulting in Lower Urinary Tract Symptoms

An Anteriorly Positioned Midline Prostatic Cyst Resulting in Lower Urinary Tract Symptoms Case Report INJ 2010;14:125-129 An Anteriorly Positioned Midline Prostatic Cyst Resulting in Lower Urinary Tract Symptoms Joo-Yong Lee, Dong-Hyuk Kang, Hee-Young Park, Jung-Soo Park, Young-Woo Son, Hong-Sang

More information

Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection

Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection DOI 10.1186/s40064-016-3176-3 RESEARCH Open Access Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection Yuxiao Zheng, Yuan Huang, Gong

More information

AGE-SPECIFIC REFERENCE RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN IN BLACK MEN. The New England Journal of Medicine

AGE-SPECIFIC REFERENCE RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN IN BLACK MEN. The New England Journal of Medicine AGE-SPECIFIC REFERENCE RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN IN BLACK MEN TED O. MORGAN, M.D., STEVEN J. JACOBSEN, M.D., PH.D., WILLIAM F. MCCARTHY, PH.D., DEBRA J. JACOBSON, M.S., DAVID G. MCLEOD,

More information

Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases

Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,

More information

Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?

Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter? ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate

More information

Introduction. Objective To investigate the clinical significance of the 1.13 ng/ml, P<0.001) and a lower free-to-total PSA

Introduction. Objective To investigate the clinical significance of the 1.13 ng/ml, P<0.001) and a lower free-to-total PSA British Journal of Urology (1998), 81, 532 538 Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA

More information

Are extended biopsies really necessary to improve prostate cancer detection?

Are extended biopsies really necessary to improve prostate cancer detection? (2003) 6, 250 255 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Are extended biopsies really necessary to improve prostate cancer detection? R Damiano*,1, R

More information

Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer

Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer Original papers Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer Tomaž Smrkolj 1, A F, Borut Gubina 1, B, E, F, Jure Bizjak 1, B, E, F, Kristina

More information

PROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging

PROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging PROSTATE MRI Dr. Margaret Gallegos Radiologist Santa Fe Imaging Topics of today s talk How does prostate MRI work? Definition of multiparametric (mp) MRI Anatomy of prostate gland and MRI imaging Role

More information

Although the test that measures total prostate-specific antigen (PSA) has been

Although the test that measures total prostate-specific antigen (PSA) has been ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the

More information

ONCOLOGY LETTERS 8: , 2014

ONCOLOGY LETTERS 8: , 2014 1834 Systematic 12 and 13 core transrectal ultrasound or magnetic resonance imaging guided biopsies significantly improve prostate cancer detection rate: A single center 13 year experience GONG CHENG *,

More information

Elevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017

Elevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,

More information

The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy

The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy Research Article TheScientificWorldJOURNAL (2009) 9, 343 348 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.47 The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial

More information

Original Article - Urological Oncology. Ho Gyun Park 1, Oh Seok Ko 1, Young Gon Kim 1, Jong Kwan Park 1-4

Original Article - Urological Oncology. Ho Gyun Park 1, Oh Seok Ko 1, Young Gon Kim 1, Jong Kwan Park 1-4 www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.4.249 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.4.249&domain=pdf&date_stamp=2014-04-17

More information

Age Specific Reference Levels of Serum. Volume and Prostate Specific Antigen. Density in Healthy Iranian Men

Age Specific Reference Levels of Serum. Volume and Prostate Specific Antigen. Density in Healthy Iranian Men ISSN 1735-1383 Iran. J. Immunol. March 2009, 6 (1), 40-48 Abdol Aziz Khezri, Mehdi Shirazi, Seyyed Mohammad Taghi Ayatollahi, Mehrzad Lotfi, Mehrdad Askarian, Ali Ariafar, Mohammad Amin Afrasiabi Age Specific

More information

or more transrectal ultrasonography (TRUS)-guided ng/ml and 39% if it was 20.0 ng/ml. of >10 ng/ml have prostate cancer [3], many other

or more transrectal ultrasonography (TRUS)-guided ng/ml and 39% if it was 20.0 ng/ml. of >10 ng/ml have prostate cancer [3], many other BJU International (1999), 83, 34 38 Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? G.C. DURKAN

More information

The Journal of International Medical Research 2012; 40:

The Journal of International Medical Research 2012; 40: The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment

More information

Korean Urologist s View of Practice Patterns in Diagnosis and Management of Benign Prostatic Hyperplasia: A Nationwide Survey

Korean Urologist s View of Practice Patterns in Diagnosis and Management of Benign Prostatic Hyperplasia: A Nationwide Survey Original Article DOI 10.3349/ymj.2010.51.2.248 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 51(2):248-252, 2010 Korean Urologist s View of Practice Patterns in Diagnosis and Management of Benign Prostatic

More information

Prostate CancerTest TM. Test Report

Prostate CancerTest TM. Test Report Test Report Patient Information Requisition Number Patient Name ID Number Date of Birth Gender M Patient Phone Number Patient E-mail Name of Lab Lab Phone Number Name of Physician Date of Collection Date

More information

Screening for Prostate Cancer Using Prostate-specific Antigen Alone asafirst-linecheckupparameter:resultsofthehealthcheckup System

Screening for Prostate Cancer Using Prostate-specific Antigen Alone asafirst-linecheckupparameter:resultsofthehealthcheckup System Jpn J Clin Oncol 2000;30(2)95 100 Screening for Prostate Cancer Using Prostate-specific Antigen Alone asafirst-linecheckupparameter:resultsofthehealthcheckup System Katsunori Uchida 1, Hitoshi Takeshima

More information

Age-Specific Reference Ranges for PSA in the Detection of Prostate Cancer

Age-Specific Reference Ranges for PSA in the Detection of Prostate Cancer Age-Specific Reference Ranges for PSA in the Detection of Prostate Cancer Review Article [1] April 01, 1997 By Edward P. Deantoni, PhD [2] PSA is the best tumor marker yet discovered. Age-specific reference

More information

The Prostate Specific-Antigen (PSA):

The Prostate Specific-Antigen (PSA): The Prostate Specific-Antigen (PSA): Why it could not detect prostate cancer reliably in the past and How it became a sensitive and specific tumor marker Hans H. Glaettli, dipl. Phys. ETH 0. Summary PSA

More information

Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer

Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer

More information

All about the Prostate

All about the Prostate MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,

More information

AVOID A POTENTIALLY UNNECESSARY REPEAT PROSTATE BIOPSY. The Progensa PCA3 test

AVOID A POTENTIALLY UNNECESSARY REPEAT PROSTATE BIOPSY. The Progensa PCA3 test AVOID A POTENTIALLY UNNECESSARY REPEAT PROSTATE BIOPSY The Progensa PCA3 test is the first FDA-approved prostate cancer-specific test of its kind that helps you and your doctor decide if a repeat biopsy

More information

National Prostate Cancer GP Referral Guideline

National Prostate Cancer GP Referral Guideline National Prostate Cancer GP Referral Guideline 2018 National Prostate Cancer GP Referral Guideline: Epidemiology Prostate cancer is the leading cause of cancer in men (excluding Non Melanoma Skin Cancer).

More information

Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio

Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio European Urology European Urology 45 (2004) 160 165 Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio Gunnar Aus a,*, Charlotte Becker b, Stefan

More information

ORIGINAL ARTICLE. Omer Gokhan Doluoglu 1, Cavit Ceylan 2, Fatih Kilinc 1, Eymen Gazel 2, Berkan Resorlu 1, Oner Odabas 2

ORIGINAL ARTICLE. Omer Gokhan Doluoglu 1, Cavit Ceylan 2, Fatih Kilinc 1, Eymen Gazel 2, Berkan Resorlu 1, Oner Odabas 2 ORIGINAL ARTICLE Vol. 42 (2): 346-350, March - April, 2016 doi: 10.1590/S1677-5538.IBJU.2015.0082 Is there any association between National Institute of Health category IV prostatitis and prostate-specific

More information

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT Frequently-Asked Questions What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication of prostate cancer, is available to you if you want

More information

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last

More information

RELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

RELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA American Urological Association symptom index for BPH RELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, AND DISEASE-SPECIFIC QUALITY OF LIFE QUESTION IN PATIENTS WITH

More information

Serum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen Study

Serum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen Study european urology 51 (2007) 1645 1653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia Serum Prostate-Specific Antigen as a Predictor of Prostate

More information

Clinical Significance of National Institutes of Health Classification in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Clinical Significance of National Institutes of Health Classification in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.4.276 Original Article - Infection/Inflammation http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.4.276&domain=pdf&date_stamp=2014-04-17

More information

Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma

Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma Disease Markers 19 (2003,2004) 287 292 287 IOS Press Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma V. Thakur a,, P.P. Singh b, M. Talwar c and U. Mukherjee

More information

Serum prostate-specific antigen as a predictor of prostate volume in Sudanese patients with benign prostatic hyperplasia

Serum prostate-specific antigen as a predictor of prostate volume in Sudanese patients with benign prostatic hyperplasia International Research on Medical Sciences Vol.2(3), pp. 034-038, July, 2014 Available online at http://www.apexjournal.org ISSN 2315-8845 2014 Apex Journal International Full Length Research Serum prostate-specific

More information

The Significance of Plasma C-reactive Protein in Patients With Elevated Serum Prostate-specific Antigen Levels

The Significance of Plasma C-reactive Protein in Patients With Elevated Serum Prostate-specific Antigen Levels Urol Sci 2010;21(2):88 92 ORIGINAL ARTICLE The Significance of Plasma C-reactive Protein in Patients With Elevated Serum Prostate-specific Antigen Levels Chang-Chi Chang 1,2,3, Alex T.L. Lin 2,3 *, Kuang-Kuo

More information

Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP

Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of

More information

Questions and Answers About the Prostate-Specific Antigen (PSA) Test

Questions and Answers About the Prostate-Specific Antigen (PSA) Test CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Questions and Answers

More information

Diagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center

Diagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition

More information

Subject Review. Prostate-Specific Antigen: Critical Issues for the Practicing Physician

Subject Review. Prostate-Specific Antigen: Critical Issues for the Practicing Physician Subject Review Prostate-Specific Antigen: Critical Issues for the Practicing Physician HERBERT C. RUCKLE, M.D.,* GEORGE G. KLEE, M.D., PH.D., AND JOSEPH E. OESTERLING, M.D. Background: Serum prostate-specific

More information

Computer simulated additional deep apical biopsy enhances cancer detection in palpably benign prostate gland

Computer simulated additional deep apical biopsy enhances cancer detection in palpably benign prostate gland Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd? 200613?12901295Original ArticleAdditional apical biopsy in prostatic gland

More information

The discovery of prostate-specific antigen

The discovery of prostate-specific antigen Review Article DISCOVERY OF PSA RAO et al. The discovery of prostate-specific antigen Amrith Raj Rao, Hanif G. Motiwala and Omer M.A. Karim Department of Urology, Wexham Park Hospital, Wexham, Berkshire,

More information

Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano

Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it

More information

The Role of TURP in the Detection of Prostate Cancer in BPH Patients with Previously Negative Prostate Biopsy

The Role of TURP in the Detection of Prostate Cancer in BPH Patients with Previously Negative Prostate Biopsy www.kjurology.org DOI:10.4111/kju.2010.51.5.313 Urological Oncology The Role of TURP in the Detection of Prostate Cancer in BPH Patients with Previously Negative Prostate Biopsy Dae Keun Kim, Sang Jin

More information

BPH with persistently elevated PSA 아주대학교김선일

BPH with persistently elevated PSA 아주대학교김선일 BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547

More information

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT FREQUENTLY-ASKED QUESTIONS

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT FREQUENTLY-ASKED QUESTIONS The British Association of Urological Surgeons 35-43 Lincoln s Inn Fields London WC2A 3PE Phone: Fax: Website: E-mail: +44 (0)20 7869 6950 +44 (0)20 7404 5048 www.baus.org.uk admin@baus.org.uk ADVICE TO

More information

ORIGINAL ARTICLE Urology INTRODUCTION

ORIGINAL ARTICLE Urology INTRODUCTION ORIGINAL ARTICLE Urology DOI: 10.3346/jkms.2011.26.1.85 J Korean Med Sci 2011; 26: 85-91 Initial Biopsy Outcome Prediction in Korean Patients- Comparison of a Novel Web-based Korean Prostate Cancer Risk

More information

Prostate-Specific Antigen in 2006: Effective Use in Benign Prostatic Hyperplasia and Prostate Cancer

Prostate-Specific Antigen in 2006: Effective Use in Benign Prostatic Hyperplasia and Prostate Cancer Volume 1, Number 3 ISSN: 1932-9245 Weill Medical College of Cornell University Reports on Men s Urologic Health 1 Editor: Steven A. Kaplan, MD, Professor of Urology, and Chief, Institute for Bladder and

More information

Original Article. Introduction. Xin LIU 1, *Jie TANG 2, Xiang FEI 2, Qiu-Yang LI 2

Original Article. Introduction. Xin LIU 1, *Jie TANG 2, Xiang FEI 2, Qiu-Yang LI 2 Original Article Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less Xin LIU 1, *Jie TANG 2, Xiang

More information

Optimal Baseline Prostate-Specific Antigen Level to Distinguish Risk of Prostate Cancer in Healthy Men Between 40 and 69 Years of Age

Optimal Baseline Prostate-Specific Antigen Level to Distinguish Risk of Prostate Cancer in Healthy Men Between 40 and 69 Years of Age ORIGINAL ARTICLE Oncology & Hematology http://dx.doi.org/.46/jkms..7..4 J Korean Med Sci ; 7: 4-45 Optimal Baseline Prostate-Specific Antigen Level to Distinguish Risk of Prostate Cancer in Healthy Men

More information

Screening for prostatic carcinoma: case finding is not the problem

Screening for prostatic carcinoma: case finding is not the problem Personal View Ann Clin Biochem 1997; 34: 333-338 Screening for prostatic carcinoma: case finding is not the problem M W France and C J Seneviratne From the Department ofclinical Biochemistry, Manchester

More information

Prostate Specific Antigen in a Community-Based Sample of Men Without Prostate Cancer: Correlations With Prostate Volume, Age, Body

Prostate Specific Antigen in a Community-Based Sample of Men Without Prostate Cancer: Correlations With Prostate Volume, Age, Body The Prostate 27:24 1-249 (I 995) Prostate Specific Antigen in a Community-Based Sample of Men Without Prostate Cancer: Correlations With Prostate Volume, Age, Body Mass Index, and Symptoms of Prostatism

More information

Int J Clin Exp Pathol 2017;10(6): /ISSN: /IJCEP Yu Chen, Jin Hu, Liang Yan, Junlong Zhang, Liang Zhao

Int J Clin Exp Pathol 2017;10(6): /ISSN: /IJCEP Yu Chen, Jin Hu, Liang Yan, Junlong Zhang, Liang Zhao Int J Clin Exp Pathol 2017;10(6):7177-7182 www.ijcep.com /ISSN:1936-2625/IJCEP0045038 Original Article The value of PSA and its derivative indexes on improving the discrimination between NIH-IV prostatitis

More information

Dichotomous Estimation of Prostate Volume: A Diagnostic Study of the Accuracy of the Digital Rectal Examination

Dichotomous Estimation of Prostate Volume: A Diagnostic Study of the Accuracy of the Digital Rectal Examination pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2013 December 31(3): 220-225 http://dx.doi.org/10.5534/wjmh.2013.31.3.220 Original Article Dichotomous Estimation of Prostate Volume: A Diagnostic

More information

The Prevalence and Characteristic Differences in Prostatic Calcification between Health Promotion Center and Urology Department Outpatients

The Prevalence and Characteristic Differences in Prostatic Calcification between Health Promotion Center and Urology Department Outpatients www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.5.330 Voiding Dysfunction The Prevalence and Characteristic Differences in Prostatic Calcification between Health Promotion Center and Urology Department

More information

Prostate cancer screening: a wobble Balance. Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph

Prostate cancer screening: a wobble Balance. Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph Prostate cancer screening: a wobble Balance Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph Epidemiology Most common non skin malignancy in men in developed countries Third leading

More information

α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results

α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.4.248 Voiding Dysfunction α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia;

More information

Prostate-Specific Antigen (PSA) Test

Prostate-Specific Antigen (PSA) Test Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the

More information

Prostatic Diseases and Male Voiding Dysfunction

Prostatic Diseases and Male Voiding Dysfunction Prostatic Diseases and Male Voiding Dysfunction Prostatic-specific Antigen Velocity After Holmium Laser Enucleation of the Prostate: Possible Predictor for the Assessment of Treatment Effect Durability

More information

Prostate Health PHARMACIST VIEW

Prostate Health PHARMACIST VIEW Prostate Health PHARMACIST VIEW Prostate Definition Prostate is a gland made of fibromuscular tissue. It is about 4 cm and surrounds the neck of the bladder and the urethra. It produces seminal fluid.

More information

Practice Patterns of Korean Urologists for Screening and Managing Prostate Cancer according to PSA Level

Practice Patterns of Korean Urologists for Screening and Managing Prostate Cancer according to PSA Level Original Article http://dx.doi.org/10.3349/ymj.2012.53.6.1136 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 53(6):1136-1141, 2012 Practice Patterns of Korean Urologists for Screening and Managing Prostate

More information

INTEROBSERVER VARIATION OF PROSTATIC VOLUME ESTIMATION WITH DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS WITH DIFFERENT EXPERIENCES

INTEROBSERVER VARIATION OF PROSTATIC VOLUME ESTIMATION WITH DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS WITH DIFFERENT EXPERIENCES Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS Vol. 30 (6): 466-471, November - December, 2004 INTEROBSERVER

More information

Effects of prostatic inflammation on LUTS and alpha blocker treatment outcomes

Effects of prostatic inflammation on LUTS and alpha blocker treatment outcomes ORIGINAL ARTICLE Vol. 40 (3): 356-366, May - June, 2014 doi: 10.1590/S1677-5538.IBJU.2014.03.09 Effects of prostatic inflammation on LUTS and alpha blocker treatment outcomes Ha Na Lee 1, Tae-Hyoung Kim

More information

Transrectal ultrasound-guided biopsy for the diagnosis of prostate cancer

Transrectal ultrasound-guided biopsy for the diagnosis of prostate cancer Transrectal ultrasound-guided for the diagnosis of prostate cancer Adrian Haşegan Clinica de Urologie, Spitalul Clinic Judeţean de Urgenţă Sibiu Facultatea de Medicină Sibiu Abstract Transrectal ultrasound-guided

More information

MAKE REPEAT PROSTATE BIOPSY DECISIONS WITH CONFIDENCE. The Progensa PCA3 test

MAKE REPEAT PROSTATE BIOPSY DECISIONS WITH CONFIDENCE. The Progensa PCA3 test MAKE REPEAT PROSTATE BIOPSY DECISIONS WITH CONFIDENCE The Progensa PCA3 test is the first FDA-approved prostate cancer-specific test of its kind that gives you the information you need to determine if

More information

LONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA

LONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA 0022-5347/03/1702-0498/0 Vol. 170, 498 502, August 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000076140.68657.fd LONG-TERM SAFETY

More information

ORIGINAL ARTICLES P ATIE TS A D METHODS. In patients with a PSA > 50 ng/ml, where no pathology RESULTS

ORIGINAL ARTICLES P ATIE TS A D METHODS. In patients with a PSA > 50 ng/ml, where no pathology RESULTS -----.- SERUM PROSTATE-SPECIFIC ANTIGEN AS SURROGATE FOR THE HISTOLOGICAL DIAGNOSIS OF PROSTATE CANCER C F Heyns, A M audt'!, G Ahmed, H B Stopforth, G A Stellmacher, A J Visser Introduction. To determine

More information

. ORIGINAL ARTICLES SERUM PROSTATE-SPECIFIC ANTIGEN AS SURROGATE FOR THE HISTOLOGICAL DIAGNOSIS OF PROSTATE CANCER

. ORIGINAL ARTICLES SERUM PROSTATE-SPECIFIC ANTIGEN AS SURROGATE FOR THE HISTOLOGICAL DIAGNOSIS OF PROSTATE CANCER . SERUM PROSTATE-SPECIFIC ANTIGEN AS SURROGATE FOR THE HISTOLOGICAL DIAGNOSIS OF PROSTATE CANCER C F Heyns, AM Naude, G Ahmed, H B Stopforth, G A Stellmacher, A J Visser Introduction. To determine whether

More information

Changes in Surgical Strategy for Patients with Benign Prostatic Hyperplasia: 12-Year Single-Center Experience

Changes in Surgical Strategy for Patients with Benign Prostatic Hyperplasia: 12-Year Single-Center Experience www.kjurology.org DOI:10.4111/kju.2011.52.3.189 Voiding Dysfunction Changes in Surgical Strategy for Patients with Benign Prostatic Hyperplasia: 12-Year Single-Center Experience Yu Seob Shin 1, Jong Kwan

More information

THE UROLOGY GROUP

THE UROLOGY GROUP THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,

More information

Voiding Dysfunction. Jae Hyun Bae, Sun Ouck Kim 1, Eun Sang Yoo 2, Kyung Hyun Moon 3, Yoon Soo Kyung 4, Hyung Jee Kim 4

Voiding Dysfunction. Jae Hyun Bae, Sun Ouck Kim 1, Eun Sang Yoo 2, Kyung Hyun Moon 3, Yoon Soo Kyung 4, Hyung Jee Kim 4 www.kjurology.org DOI:10.4111/kju.2011.52.4.274 Voiding Dysfunction Efficacy and Safety of Low-Dose Propiverine in Patients with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia with Storage Symptoms:

More information

Benign prostatic hyperplasia (BPH) is a term that

Benign prostatic hyperplasia (BPH) is a term that 42Clinical Pharmacist February 2012 Vol 4 For older men, benign prostatic hyperplasia is a common cause of lower urinary tract symptoms such as polyuria, incomplete bladder emptying, urinary urgency and,

More information

Effect of Cystoscopy on Prostate-Specific Antigen, New Words about Old Subject

Effect of Cystoscopy on Prostate-Specific Antigen, New Words about Old Subject Original Article Effect of Cystoscopy on Prostate-Specific Antigen, New Words about Old Subject Rezakhaniha B¹, Arian Pour N 2, Siroosbakhat S 2 Abstract Background: Prostate Specific Antigen () is a protein

More information

Hyoung Woo Kim, Dae Geun Moon, Hyun Min Kim, Jong Ho Hwang, Soon Chan Kim, Sam Geuk Nam, Jun Tag Park

Hyoung Woo Kim, Dae Geun Moon, Hyun Min Kim, Jong Ho Hwang, Soon Chan Kim, Sam Geuk Nam, Jun Tag Park www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.681 Voiding Dysfunction Effect of Shifting from Combination Therapy to Monotherapy of α-blockers or 5α-Reductase Inhibitors on Prostate Volume

More information

The prostate can be affected by three conditions that may cause problems for men as they get older.

The prostate can be affected by three conditions that may cause problems for men as they get older. The Prostate Gland The Prostate gland specific to males only, located in the pelvis between the bladder and rectum. It is about the shape and size of a walnut or satsuma and gets bigger as you get older.

More information

Prostate Cancer. David Wilkinson MD Gulfshore Urology

Prostate Cancer. David Wilkinson MD Gulfshore Urology Prostate Cancer David Wilkinson MD Gulfshore Urology What is the Prostate? Male Sexual Gland Adds nutrients and fluids for sperm This fluid is added to sperm during ejaculation Urethra (urine channel)

More information

RESEARCH ARTICLE. Deep Par Kash 1, Murli Lal 1, Altaf Hussain Hashmi 1, Muhammed Mubarak 2 * Abstract. Introduction

RESEARCH ARTICLE. Deep Par Kash 1, Murli Lal 1, Altaf Hussain Hashmi 1, Muhammed Mubarak 2 * Abstract. Introduction DOI:http://dx.doi.org/10.7314/APJCP.2014.15.7.3087 RESEARCH ARTICLE Utility of Digital Rectal Examination, Serum Prostate Specific Antigen, and Transrectal Ultrasound in the Detection of Prostate Cancer:

More information

Getting to Diagnosis. Debbie Victor Uro-Oncology CNS Royal Cornwall Hospitals Trust

Getting to Diagnosis. Debbie Victor Uro-Oncology CNS Royal Cornwall Hospitals Trust Getting to Diagnosis Debbie Victor Uro-Oncology CNS Royal Cornwall Hospitals Trust GP Visit Symptoms Reduced urinary flow Difficulty starting/stopping Urgency Frequency Nocturia Because a friend/relative

More information

Controversy Surrounds Question of Who Needs to be Treated for Prostate Cancer No One Size Fits All Diagnosis or Treatment

Controversy Surrounds Question of Who Needs to be Treated for Prostate Cancer No One Size Fits All Diagnosis or Treatment For Immediate Release Media Contact: Nancy Sergeant, Sergeant Marketing, 973-334-6666, nsergeant@sergeantmarketing.com Mary Appelmann, Sergeant Marketing, 973-263-6392, mappelmann@sergeantmarketing.com

More information

Hee Young Park, Joo Yong Lee, Sung Yul Park, Seung Wook Lee, Yong Tae Kim, Hong Yong Choi, Hong Sang Moon

Hee Young Park, Joo Yong Lee, Sung Yul Park, Seung Wook Lee, Yong Tae Kim, Hong Yong Choi, Hong Sang Moon www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.2.92 Voiding Dysfunction Efficacy of Alpha Blocker Treatment According to the Degree of Intravesical Prostatic Protrusion Detected by Transrectal

More information

Controversies in Prostate Cancer Screening

Controversies in Prostate Cancer Screening Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations

More information